Baird analyst, Michael Uln, reiterated his Outperform rating on shares of NewLink Genetics (NASDAQ: NLNK) and raised his price target ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE